https://radforsk.no/wp-content/uploads/2017/08/debatt_jonas_arendalsuka_web.jpg9402048Elisabeth K. Andersenhttp://radforsk.no/wp-content/uploads/2017/09/rf_logo.pngElisabeth K. Andersen2017-08-23 12:11:542019-01-17 08:51:01Come learn more about cancer
https://radforsk.no/wp-content/uploads/2016/11/Photocure.jpg4301500Elisabeth K. Andersenhttp://radforsk.no/wp-content/uploads/2017/09/rf_logo.pngElisabeth K. Andersen2017-08-23 10:14:562019-01-17 08:51:01Photocure with revenue growth of 55% in the US
https://radforsk.no/wp-content/uploads/2017/08/Betalutin_web.jpg14172123Elisabeth K. Andersenhttp://radforsk.no/wp-content/uploads/2017/09/rf_logo.pngElisabeth K. Andersen2017-08-23 07:06:322019-01-17 08:51:01Nordic Nanovector on track to start PARADIGME
Jónas Einarsson, administrerende direktør i Radiumhospitalets Forskningsstiftelse skal delta på tre debatter under Arendalsuka. Det er viktige og aktuelle temaer som kliniske studier, et todelt helsevesen og norske kreftpasienters tilgang til den best mulige kreftbehandling, som Einarsson skal være med å debattere. Hør Einarsson her i Arendal: Sustainable, Innovative Healthcare Tirsdag 15. aug kl 15 […]
http://radforsk.no/wp-content/uploads/2017/09/rf_logo.png00Elisabeth K. Andersenhttp://radforsk.no/wp-content/uploads/2017/09/rf_logo.pngElisabeth K. Andersen2017-08-14 07:45:022019-01-17 08:51:01Vi er på Arendalsuka
Our portfolio company Nordic Nanovector shows continued progress in clinical development programmes with Betalutin® in their first quarter 2017 presentation. Luigi Costa, CEO of Nordic Nanovector, comments: “In the first quarter of 2017 we continued the positive momentum of 2016. I am pleased to report the excellent progress Nordic Nanovector is making to advance its clinical […]
http://radforsk.no/wp-content/uploads/2017/09/rf_logo.png00radforskhttp://radforsk.no/wp-content/uploads/2017/09/rf_logo.pngradforsk2017-05-24 11:03:072019-01-17 08:51:01Nordic Nanovector: Results from first quarter 2017
Our portfolio company Photocure reported a Hexvix/Cysview revenue growth of 9% to NOK 36.5 million in the first quarter of 2017 (Q1 2016: NOK 33.5), with an EBITDA of NOK 4.9 million for the Hexvix/Cysview commercial franchise. The company reported a growth of 32% for the important US market, were the company recently unveiled the […]
http://radforsk.no/wp-content/uploads/2017/09/rf_logo.png00radforskhttp://radforsk.no/wp-content/uploads/2017/09/rf_logo.pngradforsk2017-05-24 10:27:172019-01-17 08:51:01Photocure: Results for the first quarter 2017
Targovax is a clinical stage company focused on developing immuno-oncology therapies to target solid tumors. On april 25th, the company announced its first quarter 2017 results. HIGHLIGHTS FOR THE FIRST QUARTER 2017: Targovax announced encouraging top line two-year survival data from the phase I/II TG01 clinical trial in resected pancreatic cancer patients – 68%[1] […]
OncoImmunity AS was ranked fourth out of 250 applicants for the EU SME Instrument grant. OncoImmunity is one of the portfolio companies of the Radium Hospital Research Foundation and is developing innovative software solutions to guide the discovery of neoantigen-based personalized immunotherapies and biomarkers. “We applied for the SME instrument grant as it represents an […]
http://radforsk.no/wp-content/uploads/2017/09/rf_logo.png00radforskhttp://radforsk.no/wp-content/uploads/2017/09/rf_logo.pngradforsk2017-04-19 07:56:512019-01-17 08:51:01OncoImmunity wins prestigious EU grant
http://radforsk.no/wp-content/uploads/2017/09/rf_logo.png00radforskhttp://radforsk.no/wp-content/uploads/2017/09/rf_logo.pngradforsk2017-02-16 13:27:102019-01-17 08:51:01Targovax ASA: Fourth quarter and full year 2016 results
Come learn more about cancer
/in Radforsk /by Elisabeth K. AndersenWe arrange three seminars during Oslo Innovation Week and Forskningsdagene.
Photocure with revenue growth of 55% in the US
/in Portfolio Companies /by Elisabeth K. AndersenQ2 report shows significant progress in the US market
Nordic Nanovector on track to start PARADIGME
/in Portfolio Companies /by Elisabeth K. AndersenSecond quarter report shows continued solid operational progress.
Vi er på Arendalsuka
/in Radforsk /by Elisabeth K. AndersenJónas Einarsson, administrerende direktør i Radiumhospitalets Forskningsstiftelse skal delta på tre debatter under Arendalsuka. Det er viktige og aktuelle temaer som kliniske studier, et todelt helsevesen og norske kreftpasienters tilgang til den best mulige kreftbehandling, som Einarsson skal være med å debattere. Hør Einarsson her i Arendal: Sustainable, Innovative Healthcare Tirsdag 15. aug kl 15 […]
Nordic Nanovector: Results from first quarter 2017
/in Portfolio Companies /by radforskOur portfolio company Nordic Nanovector shows continued progress in clinical development programmes with Betalutin® in their first quarter 2017 presentation. Luigi Costa, CEO of Nordic Nanovector, comments: “In the first quarter of 2017 we continued the positive momentum of 2016. I am pleased to report the excellent progress Nordic Nanovector is making to advance its clinical […]
Photocure: Results for the first quarter 2017
/in Portfolio Companies /by radforskOur portfolio company Photocure reported a Hexvix/Cysview revenue growth of 9% to NOK 36.5 million in the first quarter of 2017 (Q1 2016: NOK 33.5), with an EBITDA of NOK 4.9 million for the Hexvix/Cysview commercial franchise. The company reported a growth of 32% for the important US market, were the company recently unveiled the […]
Targovax ASA: First quarter 2017 results
/in Portfolio Companies /by radforskTargovax is a clinical stage company focused on developing immuno-oncology therapies to target solid tumors. On april 25th, the company announced its first quarter 2017 results. HIGHLIGHTS FOR THE FIRST QUARTER 2017: Targovax announced encouraging top line two-year survival data from the phase I/II TG01 clinical trial in resected pancreatic cancer patients – 68%[1] […]
OncoImmunity wins prestigious EU grant
/in Portfolio Companies /by radforskOncoImmunity AS was ranked fourth out of 250 applicants for the EU SME Instrument grant. OncoImmunity is one of the portfolio companies of the Radium Hospital Research Foundation and is developing innovative software solutions to guide the discovery of neoantigen-based personalized immunotherapies and biomarkers. “We applied for the SME instrument grant as it represents an […]
Targovax ASA: Fourth quarter and full year 2016 results
/in Portfolio Companies /by radforskOur portfolio company Targovax ASA has announced its fourth quarter and full year 2016 results.